Evidence map›Paper›PMID 39296674›Full record

ArticleJournal of psoriasis and psoriatic arthritis2023

Development of Psoriasis Assessment Tools Among Patients in the CorEvitas Psoriasis Registry.

Wayne P Gulliver, Kyoungah See, Baojin Zhu, Bruce W Konicek, Ryan W Harrison, Robert R McLean, Samantha J Kerti, Russel T Burge, Craig L Leonardi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of psoriasis and psoriatic arthritis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Wayne P GulliverSt. John's, Newfoundland and Labrador, Memorial University of Newfoundland, Newfoundland, Canada.
Kyoungah SeeEli Lilly and Company, Indianapolis, IN, USA.
Baojin ZhuEli Lilly and Company, Indianapolis, IN, USA.
Bruce W KonicekEli Lilly and Company, Indianapolis, IN, USA.
Ryan W HarrisonCorEvitas LLC, Waltham, MA, USA.ORCID https://orcid.org/0000-0003-4575-006X
Robert R McLeanCorEvitas LLC, Waltham, MA, USA.
Samantha J KertiCorEvitas LLC, Waltham, MA, USA.
Russel T BurgeEli Lilly and Company, Indianapolis, IN, USA.
Craig L LeonardiCentral Dermatology, St. Louis, MO, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Dermatologists would benefit from an easy to use psoriasis severity assessment tool in the clinic. Objective: To develop psoriasis assessment tools to predict PASI and Dermatology Life Quality Index (DLQI) using simple measures typically collected in clinical practice. Methods: Data included 33 605 dermatology visits among plaque psoriasis patients enrolled in the CorEvitas Psoriasis Registry (4/15/15-7/11/20). Performance (adjusted coefficient of determination [R Results: Mean (SD) age, BSA, and PASI were 51 (14) years, 6 (11), and 4 (6), respectively; 46% were women, and 87% were biologic experienced. A model predicting PASI using BSA plus IGA performed best among a priori specified models (R Conclusion: An assessment tool for psoriasis including BSA and IGA may be an ideal option to predict PASI in a clinic setting.

Indexed as

DLQIPASIpatient-reported outcome measurespsoriasispsoriasis assessment tool

Identifiers

PMID39296674
PMCPMC11361488

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.